Free Trial

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

$4.00
+0.11 (+2.83%)
(As of 07/12/2024 ET)

Adaptive Biotechnologies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$6.80
70.00% Upside
High Forecast$10.00
Average Forecast$6.80
Low Forecast$5.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$6.80$6.80$6.80$13.80
Forecasted Upside70.00% Upside82.99% Upside82.99% Upside58.34% Upside
Get Adaptive Biotechnologies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.

ADPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ADPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Adaptive Biotechnologies Stock vs. The Competition

TypeAdaptive BiotechnologiesMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside70.00% Upside991.61% Upside9.39% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/4/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$6.00 ➝ $5.00+73.61%
2/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$11.00 ➝ $5.00+25.63%
2/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$11.00 ➝ $8.00+96.08%
11/13/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$13.00 ➝ $6.00+73.41%
11/10/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/24/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $10.00+139.23%
2/15/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderperform$7.00-26.00%
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$15.00+87.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:48 AM ET.

ADPT Forecast - Frequently Asked Questions

What is Adaptive Biotechnologies' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Adaptive Biotechnologies is $6.80, with a high forecast of $10.00 and a low forecast of $5.00.

Should I buy or sell Adaptive Biotechnologies stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ADPT shares.

Does Adaptive Biotechnologies's stock price have much upside?

According to analysts, Adaptive Biotechnologies's stock has a predicted upside of 82.99% based on their 12-month stock forecasts.

Do Wall Street analysts like Adaptive Biotechnologies more than its competitors?

Analysts like Adaptive Biotechnologies less than other "medical" companies. The consensus rating score for Adaptive Biotechnologies is 2.67 while the average consensus rating score for "medical" companies is 2.71. Learn more on how ADPT compares to other companies.


This page (NASDAQ:ADPT) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners